Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse
NCT06827860Phase 2Recruiting
- Start
- Nov 2025
- Primary completion
- Jan 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of talquetamab in multiple myeloma (MM) (2 arms). Primary endpoint: Objective Response Rate. Started Nov 2025; status: recruiting.
02
Drugs
talquetamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06827860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06827860.